ArticleMedicina oral, patologia oral y cirugia bucal2025
Vascular endothelial growth factor immunoexpression in oral paracoccidioidomycosis.
Article in Medicina oral, patologia oral y cirugia bucal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParacoccidioidomycosis (PCM) is a systemic mycosis endemic and limited to Latin America. Brazil is responsible for more than 80% of diagnosed cases in the world. Since PCM is not a notifiable disease, there are still no accurate data on its incidence in Brazil. Vascular endothelial growth factor (VEGF) is considered the main vascular endothelial growth factor expressed in the process of angiogenesis, both under physiological and pathological conditions. To date, there are not studies in the literature that evaluated the expression of VEGF in oral PCM lesions. Therefore, the objective of this study was to evaluate the prevalence of oral lesions of PCM diagnosed from 1998 to 2020; to analyze the immunoexpression of VEGF in oral lesions of PCM; and to compare the VEGF immunostaining with the clinical and microscopic aspects of these lesions. MATERIAL AND
methodsClinical data of 98 cases of patients with oral PCM were evaluated. A total of 41 selected cases were quantitatively and qualitatively analysed by immunohistochemistry for VEGF.
resultsOur results showed that oral PCM preferentially affects white males, with mean age of 50.2 years, and the gingiva and the alveolar ridge. It was not possible to correlate VEGF immunoexpression with clinical and microscopic variables.
conclusionsOral PCM is a relatively uncommon pathological condition and that, in our sample, the immunoexpression of VEGF was mild and observed in a reduced number of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.